-
Take Charge of Your Brain Health — For You and Your Loved OnesThe Arizona Department of Health Services (ADHS) joins the Alzheimer’s Association® in encouraging Arizonans to take proactive steps toward protecting their brain health and reducing the risk of cognitive…
-
Marine Veteran says, “Thank you” with ArtAfter VA discovered a tumor that others dismissed, Marine Veteran Chester Zaremba found a powerful way to say thank you—through diamond art.
-
GAMMAGARD LIQUIDProduct approval information is indicated for:
• Replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older.
• Maintenance therapy to improve muscle… -
In a First, Trump and GOP-Led Congress Prepare To Swell Ranks of U.S. UninsuredCLARKESVILLE, Ga. — Last September, Alton Fry went to the doctor concerned he had high blood pressure. The trip would result in a prostate cancer…
-
A Texas Boy Needed Protection From Measles. The Vaccine Cost $1,400.
In the early days of the West Texas measles outbreak, Thang Nguyen eyed the rising number of cases and worried. His 4-year-old son was at…
-
Nirwana Foods Issues Allergy Alert on Undeclared Sulfites on Golden Raisin 28Oz Pouch Label
Nirwana Foods of NJ is recalling its 28-ounce pouches Golden Raisin with lot number (24/351-2410) because they may contain undeclared sulfites. People who have allergies to sulfites run the risk of serious…
-
MNEXSPIKE
For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
MNEXSPIKE is approved for use in individuals who have been… -
FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies
FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies
-
TECARTUS
For the treatment of adult patients with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (B-ALL). For the treatment of adult patients with relapsed/refractory mantle cell lymphoma (r/r MCL).
-
YESCARTA
For the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Axicabtagene ciloleucel is…
- Load More
